The small leucine-rich proteoglycan, biglycan, is highly expressed in adipose tissue of Psammomys obesus and is associated with obesity and type 2 diabetes

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 67-72

  Bolton, Kristy ^a   Segal, David ^a   Walder, Ken ^a,b  

^a School of Medicine   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

Adipose tissue; Biglycan; Obesity; Psammomys obesus; Small leucine rich proteoglycan; Type 2 diabetes

Indexed keywords

BIGLYCAN; MESSENGER RNA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIGLYCAN GENE; CELL FRACTIONATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; IMPAIRED GLUCOSE TOLERANCE; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PSAMMOMYS OBESUS; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; SUBCUTANEOUS FAT; UPREGULATION;

EID: 84866748154     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s27925     Document Type: Article

References (31)

1. Bolton K, Segal D, McMillan J, et al. Decorin is a secreted protein associated with obesity and type 2 diabetes. Int J Obes (Lond). 2008;32(7): 1113-1121.
2. Fisher LW, Termine JD, Young MF. Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem. 1989;264(8):4571-4576.
3. Hildebrand A, Romaris M, Rasmussen LM, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J. 1994;302(Pt 2):527-534.
4. Schonherr E, Witsch-Prehm P, Harrach B, Robenek H, Rauterberg J, Kresse H. Interaction of biglycan with type I collagen. J Biol Chem. 1995;270(6):2776-2783.
5. Bi Y, Stuelten CH, Kilts T, et al. Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J Biol Chem. 2005;280(34): 30481-30489.
6. Young MF, Bi Y, Ameye L, Chen XD. Biglycan knockout mice: new models for musculoskeletal diseases. Glycoconj J. 2002;19(4-5): 257-262.
7. Wadhwa S, Bi Y, Ortiz AT, et al. Impaired posterior frontal sutural fusion in the biglycan/decorin double deficient mice. Bone. 2007;40(4): 861-866.
8. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol. 1997;136(3):729-743.
9. Xu T, Bianco P, Fisher LW, et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet. 1998;20(1):78-82.
10. Corsi A, Xu T, Chen XD, et al. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J Bone Miner Res. 2002;17(7):1180-1189.
11. Ameye L, Young MF. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology. 2002;12(9):107R-116R.
12. Chen XD, Fisher LW, Robey PG, Young MF. The small leucinerich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. Faseb J. 2004;18(9):948-958.
13. Casar JC, McKechnie BA, Fallon JR, Young MF, Brandan E. Transient up-regulation of biglycan during skeletal muscle regeneration: delayed fiber growth along with decorin increase in biglycan-deficient mice. Dev Biol. 2004;268(2):358-371.
14. Barnett M, Collier GR, Collier FM, Zimmet P, O'Dea K. A crosssectional and short-term longitudinal characterisation of NIDDM in Psammomys obesus. Diabetologia. 1994;37(7):671-676.
15. Rahmani M, Wong BW, Ang L, et al. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol. 2006;84(1): 77-92.
16. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular Biology of the Cell. 3rd ed: Garland Publishing; 1994.
17. Kresse H, Schonherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol. 2001;189(3):266-274.
18. Iozzo RV, Murdoch AD. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. Faseb J. 1996;10(5):598-614.
19. Smas CM, Sul HS. Control of adipocyte differentiation. Biochem J. 1995;309(Pt 3):697-710.
20. Huber J, Loffler M, Bilban M, et al. Prevention of high-fat diet-induced adipose tissue remodeling in obese diabetic mice by n-3 polyunsaturated fatty acids. Int J Obes (Lond). 2007;31(6):1004-1013.
21. Olsson U, Bondjers G, Camejo G. Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes. 1999;48(3):616-622.
22. Lehti TM, Silvennoinen M, Kivela R, Kainulainen H, Komulainen J. Effects of streptozotocin-induced diabetes and physical training on gene expression of extracellular matrix proteins in mouse skeletal muscle. Am J Physiol Endocrinol Metab. 2006; 290(5): E900-E907.
23. King VL, Hatch NW, Chan HW, de Beer MC, de Beer FC, Tannock LR. A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring). 2010;18(1):35-41.
24. Mangat R, Su J, Scott PG, Russell JC, Vine DF, Proctor SD. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem Soc Trans. 2007;35(Pt 3): 477-481.
25. Zhang W, Chuang YJ, Jin T, et al. Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells. Cancer Res. 2006;66(10):5047-5055.
26. Ward M, Ajuwon KM. Regulation of pre-adipocyte proliferation and apoptosis by the small leucine-rich proteoglycans, biglycan and decorin. Cell Prolif. 2011;44(4):343-351.
27. Moreth K, Brodbeck R, Babelova A, et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest. 2010;120(12):4251-4272.
28. Babelova A, Moreth K, Tsalastra-Greul W, et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem. 2009;284(36):24035-24048.
29. Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005;115(8):2223-2233.
30. Torres-Leal FL, Fonseca-Alaniz MH, Rogero MM, Tirapegui J. The role of inflamed adipose tissue in the insulin resistance. Cell Biochem Funct. 2010;28(8):623-631.
31. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111-1119.